Top

Published in:

2012 | OriginalPaper | Chapter

32. Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification

Authors : Marie M. Zhu, Michael Mollet, Rene S. Hubert

Published in: Handbook of Industrial Chemistry and Biotechnology

Publisher: Springer US

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

The biotechnology and pharmaceutical industries have seen a recent surge in the development of biological drug products manufactured from engineered mammalian cell lines. Since the hugely successful launch of human tissue plasminogen activator in 1987 and erythropoietin in 1988, the biopharmaceutical market has grown immensely. Global sales in 2003 exceeded US $30 billion [1]. Currently, a total of 108 biotherapeutics are approved and available to patients (Table 32.1). In addition, 324 medically related, biotechnology-derived medicines for nearly 150 diseases are in clinical trials or under review by the US Food and Drug Administration [2]. These biopharmaceutical candidates promise to bring more and better treatments to patients. Compared to small molecule drugs, biotherapeutics show exquisite specificity with fewer off-target interactions and improved safety profiles. Protein engineering technologies have advanced to create protein drugs with improved efficacy, specificity, stability, pharmacokinetics, and solubility. Strategies that have been employed to implement these changes include mutagenesis, recombination, and other directed evolution methods, as well as rational design and structure-based computational approaches [3–7]. These advanced protein engineering technologies are creating novel drug designs and clever treatment strategies that are fuelling the biopharmaceutical market growth.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

inform now

previous chapter Industrial Enzymes and Biocatalysis

next chapter Biomass Conversion

Walsh G (2003) Biopharmaceutical benchmarks—2003. Nat Biotechnol 21:865–870CrossRef

PhRMA (2004) 324 biotechnology medicines in testing promise to bolster the arsenal against disease. New medicines in development. Accessed Oct 25, 2004. http://www.phrma.org/newmedicines/biotech/

Graddis TJ, Remmele RL Jr, McGrew JT (2002) Designing proteins that work using recombinant technologies. Curr Pharm Biotechnol 3:285–297CrossRef

Brekke OH, Loset GA (2003) New technologies in therapeutic antibody development. Curr Opin Pharmacol 3:544–550CrossRef

Lazar GA, Marshall SA, Plecs JJ, Mayo SL, Desjarlais JR (2003) Designing proteins for therapeutic applications. Curr Opin Struct Biol 13:513–518CrossRef

Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR (2003) Rational design and engineering of therapeutic proteins. Drug Discov Today 8:212–221CrossRef

Vasserot AP, Dickinson CD, Tang Y, Huse WD, Manchester KS, Watkins JD (2003) Optimization of protein therapeutics by directed evolution. Drug Discov Today 8:118–126CrossRef

Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393–1398CrossRef

Arden N, Nivtchanyong T, Betenbaugh MJ (2004) Cell engineering blocks stress and improves biotherapeutic production. Bioprocessing 3:23–28

10.

Running Deer J, Allison DS (2004) High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1alpha gene. Biotechnol Prog 20:880–889CrossRef

11.

Brinster RL, Allen JM, Behringer RR, Gelinas RE, Palmiter RD (1988) Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci U S A 85:836–840CrossRef

12.

Palmiter RD, Sandgren EP, Avarbock MR, Allen DD, Brinster RL (1991) Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci U S A 88:478–482CrossRef

13.

Pestova TV, Lomakin IB, Hellen CU (2004) Position of the CrPV IRES on the 40S subunit and factor dependence of IRES/80S ribosome assembly. EMBO Rep 5:906–913CrossRef

14.

Zahn-Zabal M, Kobr M, Girod PA, Imhof M, Chatellard P, de Jesus M, Wurm F, Mermod N (2001) Development of stable cell lines for production or regulated expression using matrix attachment regions. J Biotechnol 87:29–42CrossRef

15.

Kim JM, Kim JS, Park DH, Kang HS, Yoon J, Baek K, Yoon Y (2004) Improved recombinant gene expression in CHO cells using matrix attachment regions. J Biotechnol 107:95–105CrossRef

16.

Harland L, Crombie R, Anson S, deBoer J, Ioannou PA, Antoniou M (2002) Transcriptional regulation of the human TATA binding protein gene. Genomics 79:479–482CrossRef

17.

Wong TK, Newmann E (1982) Electric-field mediated gene-transfer. Biochem Biophys Res Commun 107:584–587CrossRef

18.

Kichler A (2004) Gene transfer with modified polyethylenimines. J Gene Med 6(Suppl 1):S3–10CrossRef

19.

Cockett MI, Bebbington CR, Yarranton GT (1990) High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnol (N Y) 8:662–667CrossRef

20.

Lucas BK, Giere LM, DeMarco RA, Shen A, Chisholm V, Crowley CW (1996) High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector. Nucleic Acids Res 24:1774–1779CrossRef

21.

Kim SJ, Lee GM (1999) Cytogenetic analysis of chimeric antibody-producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their5t stability in the absence of selective pressure. Biotechnol Bioeng 64:741–749CrossRef

22.

Fann CH, Guirgis F, Chen G, Lao MS, Piret JM (2000) Limitations to the amplification and stability of human tissue-type plasminogen activator expression by Chinese hamster ovary cells. Biotechnol Bioeng 69:204–212CrossRef

23.

Yoshikawa T, Nakanishi F, Ogura Y, Oi D, Omasa T, Katakura Y, Kishimoto M, Suga K (2000) Amplified gene location in chromosomal DNA affected recombinant protein production and stability of amplified genes. Biotechnol Prog 16:710–715CrossRef

24.

Brezinsky SC, Chiang GG, Szilvasi A, Mohan S, Shapiro RI, MacLean A, Sisk W, Thill G (2003) A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity. J Immunol Methods 277:141–155CrossRef

25.

Ham RG (1981) Tissue growth factors. In: Baserga R (ed) Handbook of experimental pharmacology. Springer, New York, p 13

26.

Sato GH, Pardee A, Sirbasku DA (eds) (1982) Growth of cells in hormonally defined media, cold spring harbor conference on cell proliferation, vol 9. Cold Spring Harbor Press, Cold Spring Harbor, NY

27.

Fletcher T (2005) Designing culture media for recombinant protein production: A rational approach. BioProcess Int 3:30–36

28.

Lee GM, Kim EJ, Kim NS, Yoon SK, Ahn YH, Song JY (1999) Development of a serum-free medium for the production of erythropoietin by suspension culture of recombinant Chinese hamster ovary cells using a statistical design. J Biotechnol 69:85–93CrossRef

29.

Liu C, Chu I, Hwang S (2001) Factorial designs combined with the steepest ascent method to optimize serum-free media for CHO cells. Enzyme Microb Technol 28:314–321CrossRef

30.

Chun C, Heineken K, Szeto D, Ryll T, Chamow S, Chung JD (2003) Application of factorial design to accelerate identification of CHO growth factor requirements. Biotechnol Prog 19:52–57CrossRef

31.

Allison DW, Aboytes KA, Fong DK, Leugers SL, Johnson TK, Loke HN, Donahue LM (2005) Development and optimization of cell culture media: Genomic and proteomic approaches. BioProcess Int 31:38–45

32.

Zhu MM, Lee ES, Hermans WR, Wasilko DJ (2001) Overview and serum-free medium development for mammalian cell culture. Fourth Conference on recent advances in fermentation technology (RAFTIV), Nov 11–13, Long Beach, CA

33.

Varley J, Birch J (1999) Reactor design for large scale suspension animal cell culture. Cytotechnol 29:177–205CrossRef

34.

Ozturk SS (1996) Engineering challenges in high density cell culture systems. Cytotechnol 22:3–16CrossRef

35.

Myers KJ, Reeder MF, Fasano JB (2002) Optimize mixing by using the proper baffles. Chem Eng Progress 98:42–47

36.

Chisti Y (1993) Animal cell culture in stirred bioreactors: Observations on scale-up. Bioprocess Eng 9:191–196CrossRef

37.

Pattison RN, Swamy J, Mendenhall B, Hwang C, Frohlich BT (2000) Measurement and control of dissolved carbon dioxide in mammalian cell culture processes using an in situ fiber optic chemical sensor. Biotechnol Prog 16:769–774CrossRef

38.

Dowd JE, Jubb A, Kwok KE, Piret JM (2003) Optimization and control of perfusion cultures using a viable cell probe and cell specific perfusion rates. Cytotechnol 42:35–45CrossRef

39.

Noll T, Biselli M (1998) Dielectric spectroscopy in the cultivation of suspended and immobilized hybridoma cells. J Biotechnol 63:187–198CrossRef

40.

Gupta A, Rao G (2003) A study of oxygen transfer in shake flasks using a non-invasive oxygen sensor. Biotechnol Bioeng 84:351–358CrossRef

41.

Ge X, Kostov Y, Rao G (2005) Low-cost noninvasive optical CO₂ sensing system for fermentation and cell culture. Biotechnol Bioeng 89:329–334CrossRef

42.

Singh V (1999) Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnol 30:149–158CrossRef

43.

Ozturk SS (2005) Batch versus perfusion: a real case comparison of highly developed cell culture processes for the production of monoclonal antibodies. 229th National Meeting American Chemical Society, Mar 13–17, San Diego, CA

44.

Voisard D, Meuwly F, Ruffieux PA, Baer G, Kadouri A (2003) Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol Bioeng 82:751–765CrossRef

45.

Alrubeai M, Singh RP, Emery AN, Zhang Z (1995) Cell cycle and cell size dependence of susceptibility to hydrodynamic forces. Biotechnol Bioeng 46:88–92CrossRef

46.

Alrubeai M, Singh RP, Goldman MH, Emery AN (1995) Death mechanisms of animal cells in conditions of intensive agitation. Biotechnol Bioeng 45:463–472CrossRef

47.

Gregoriades N, Clay J, Ma N, Koelling K, Chalmers JJ (2000) Cell damage of microcarrier cultures as a function of local energy dissipation created by a rapid extensional flow. Biotechnol Bioeng 69:171–182CrossRef

48.

Ma N, Koelling KW, Chalmers JJ (2002) Fabrication and use of a transient contractional flow device to quantify the sensitivity of mammalian and insect cells to hydrodynamic forces. Biotechnol Bioeng 80:428–437CrossRef

49.

Kunas KT, Papoutsakis ET (1990) Damage mechanisms of suspended animal cells in agitated bioreactors with and without bubble entrainment. Biotechnol Bioeng 36:476–483CrossRef

50.

Chattopadhyay D, Rathman JF, Chalmers JJ (1995) Thermodynamic approach to explain cell adhesion to air-medium interfaces. Biotechnol Bioeng 48:649–658CrossRef

51.

Ma N, Chalmers JJ, Aunins JG, Zhou W, Xie L (2004) Quantitative studies of cell-bubble interactions and cell damage at different Pluronic F-68 and cell concentrations. Biotechnol Prog 20:1183–1191CrossRef

52.

Osman JJ, Birch J, Varley J (2001) The response of GS-NS0 myeloma cells to pH shifts and pH perturbations. Biotechnol Bioeng 75:63–73CrossRef

53.

Sauer PW, Burky JE, Wesson MC, Sternard HD, Qu L (2000) A high-yielding, generic fed-batch cell culture process for production of recombinant antibodies. Biotechnol Bioeng 67:585–597CrossRef

54.

Lao MS, Toth D (1997) Effects of ammonium and lactate on growth and metabolism of a recombinant Chinese hamster ovary cell culture. Biotechnol Prog 13:688–691CrossRef

55.

Ozturk SS, Thrift JC, Blackie JD, Naveh D (1997) Real-time monitoring and control of glucose and lactate concentrations in a mammalian cell perfusion reactor. Biotechnol Bioeng 53:372–378CrossRef

56.

Martinelle K, Westlund A, Haggstrom L (1996) Ammonium ion transport: A cause of cell death. Cytotechnol 22:251–254CrossRef

57.

Genzel Y, Ritter JB, Konig S, Alt R, Reichl U (2005) Substitution of glutamine by pyruvate to reduce ammonia formation and growth inhibition of mammalian cells. Biotechnol Prog 21:58–69CrossRef

58.

Yang M, Butler M (2000) Effect of ammonia on the glycosylation of human recombinant erythropoietin in culture. Biotechnol Prog 16:751–759CrossRef

59.

Gray DR, Chen S, Howarth W, Inlow D, Maiorella BL (1996) CO₂ in large-scale and high-density CHO cell perfusion culture. Cytotechnol 22:65–78CrossRef

60.

deZengotita VM, Schmelzer AE, Miller WM (2002) Characterization of hybridoma cell responses to elevated pCO₂ and osmolality: Intracellular pH, cell size, apoptosis, and metabolism. Biotechnol Bioeng 77:369–380CrossRef

61.

Zhu MM, Goyal A, Rank DL, Gupta SK, Vanden Boom T, Lee SS (2005) Effects of elevated pCO₂ and osmolality on growth of CHO cells and production of antibody-fusion protein B1: A case study. Biotechnol Prog 21:70–77CrossRef

62.

Mostafa SS, Gu X (2003) Strategies for improved dCO₂ removal in large-scale fed-batch cultures. Biotechnol Prog 19:45–51CrossRef

63.

Chen ZL (2004) Temperature shift as a process optimization step for the production of pro-urokinase by a recombinant Chinese hamster ovary cell line in high-density perfusion culture. J Biosci Bioeng 97:239–243

64.

Clark KJ, Chaplin FW, Harcum SW (2004) Temperature effects on product-quality-related enzymes in batch CHO cell cultures producing recombinant tPA. Biotechnol Prog 20:1888–1892CrossRef

65.

Fox SR, Patel UA, Yap MG, Wang DI (2004) Maximizing interferon-gamma production by Chinese hamster ovary cells through temperature shift optimization: Experimental and modeling. Biotechnol Bioeng 85:177–184CrossRef

66.

Bollati-Fogolin M, Forno G, Nimtz M, Conradt HS, Etcheverrigaray M, Kratje R (2005) Temperature reduction in cultures of hGM-CSF-expressing CHO cells: Effect on productivity and product quality. Biotechnol Prog 21:17–21CrossRef

67.

Dempsey J, Ruddock S, Osborne M, Ridley A, Sturt S, Field R (2003) Improved fermentation processes for NS0 cell lines expressing human antibodies and glutamine synthetase. Biotechnol Prog 19:175–178CrossRef

68.

Wong DCF, Wong KTK, Goh LT, Heng CK, Yap MGS (2005) Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. Biotechnol Bioeng 89:164–177CrossRef

69.

Dowd JE, Kwok KE, Piret JM (2000) Increased t-PA yields using ultrafiltration of an inhibitory product from CHO fed-batch culture. Biotechnol Prog 16:786–794CrossRef

70.

Dowd JE, Kwok KE, Piret JM (2001) Predictive modeling and loose-loop control for perfusion bioreactors. Biochem Eng J 9:1–9CrossRef

71.

Nienow AW, Langheinrich C, Stevenson NC, Emery AN, Clayton TM, Slater NKH (1996) Homogenisation and oxygen transfer rates in large agitated and sparged animal cell bioreactors: Some implications for growth and production. Cytotechnol 22:87–94CrossRef

72.

Gardner AR, Smith TM (2000) Identification and establishment of operating ranges of critical process variables. In: Sofer G, Zabriskie DW (eds) Biopharmaceutical process validation. Marcel Dekker, New York, pp 61–76

73.

Moran EB, McGowan ST, McGuire JM, Frankland JE, Oyebade IA, Waller W, Archer LC, Morris LO, Pandya J, Nathan SR, Smith L, Cadette ML, Michalowski JT (2000) A systematic approach to the validation of process control parameters for monoclonal antibody production in fed-batch culture of a murine myeloma. Biotechnol Bioeng 69:242–255CrossRef

74.

Lyddiatt A (1981) Downstream processing: Protein recovery. In: Butler M (ed) Mammalian cell biotechnology: a practical approach. IRL Press at Oxford University Press, New York, pp 187–206

75.

Bennan J, Bing F, Boone H, Fernandez J, Seely B, van Deinse H, Miller D (2002) Evaluation of extractables from product-contact surfaces. Biopharm Int 15:22–34

76.

Kemp G, O’Neil P (2004) Large-scale production of therapeutic antibodies: Considerations for optimizing product capture and purification. In: Subramanian G (ed) Antibodies, vol 1, Production and purification. Kluwer, Boston, pp 75–100CrossRef

77.

Burton S (2002) A generic approach to the purification of monoclonal antibodies: An alternative to protein A. IBC Conference: antibody production & downstream processing, Feb 13–15, San Diego, CA

78.

Jacob LR, Frech M (2004) Scale-up of antibody purification. In: Subramanian G (ed) Antibodies, vol 1, Production and purification. Kluwer, Boston, pp 101–131CrossRef

79.

Gattschalk U (2005) Large scale manufacturing of mAbs and the backlog in bioseparation technologies. IBC Conference: antibody production & downstream processing, March 8–11, San Diego, CA

80.

Hubbard B (2005) Platform approaches to monoclonal antibody purification. IBC Conference: antibody production & downstream processing, Mar 8–11, San Diego, CA

81.

Fish B (2002) Taking a monoclonal antibody from mg to kg scale: Production strategies, issues and successes. IBC Conference: Scaling-up From Bench to Clinic and Beyond, Aug 14–16, San Diego, CA

82.

Aranha-Creado H (1998) Clearance of murine leukaemia virus from monoclonal antibody solutions by a hydrophilic PVDF microporous membrane filter. Biologicals 26:167–172CrossRef

83.

Rathore A, Velaydhan A (2003) Guidelines for optimization and scale-up in preparative chromatography. Biopharm Int 16:34–42

Title: Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification
Authors: Marie M. Zhu
Michael Mollet
Rene S. Hubert
Publisher: Springer US
Book: Handbook of Industrial Chemistry and Biotechnology
Print ISBN: 978-1-4614-4258-5

Electronic ISBN: 978-1-4614-4259-2

Copyright Year: 2012
DOI: https://doi.org/10.1007/978-1-4614-4259-2_32